Work

Pediatric flecainide pharmacogenomics: a roadmap to delivering precision-based care to pediatrics arrhythmias

Year: 2024

Type: review

Abstract: Flecainide acetate is a Class 1c anti-arrhythmic with a potent sodium voltage gated channel blockade which is utilized for the second-line treatment of tachyarrhythmias in children and adults. Given its narrow therapeutic index, the individualization of drug therapy is of utmost importance for clinicians. Despite efforts to improve anti-arrhythmic drug therapy, there remain knowledge gaps regarding the impact of variation in the genes relevant to flecainide's disposition and response. This variability is compounded in developing children whose drug disposition and response pathways may remain immature. The purpose of this comprehensive review is to outline flecainide's disposition and response pathways while simultaneously highlighting opportunities for prospective investigation in the pediatric population.

Source: Frontiers in Pharmacology

DOI: 10.3389/fphar.2024.1477485

Authors: Ronald Palmen, Mollie Walton, Jonathan Wagner

Institutions: University of Missouri–Kansas City, Children's Mercy Hospital

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,295